Open Access Research Article survival in the heart [1,2], lung [3, 4] , and liver [5] transplants. However, careful investigation of these studies demonstrates that ABO-compatible transplants have lower graft survival than identical transplants in some of these studies, though the differences do not reach statistical significance. Koukoutisis [6] and Bjoro [7] reported that ABO-compatible liver transplant recipients actually have significantly lower graft and patient survival than ABO-identical transplant patients.
Introduction
ABO-compatible but non-identical transplants have been performed in all organ types for decades. It is controversial whether ABO-compatible transplants have comparable outcomes compared to identical transplants. Some studies have shown ABO-compatible and identical transplants have similar graft and Transplantation Network and were included in this study. Among them, 2,061 (90.3%) patients received ABO-identical transplants and 222 patients (9.7%) received ABO-compatible transplants. Four patients who received ABO incompatible intestinal transplants were excluded from this study. Patient demographics of ABO-compatible and ABO-identical transplant recipients are summarized in Table 1 .
Statistical Analysis
All statistical analyses were performed using STATA version 13 (StataCorp LP, College Station, TX) with all available updates as of January 2015. The difference in the distribution of categorical variables between groups was investigated using the chi-square test. Unpaired-test or one-way analysis of variance was used for numerical variables. Graft survival rates of transplant recipients were estimated using Kaplan-Meier methods, with significance determined by log-rank test.
To determine whether ABO-compatible but non-identical transplantation is an independent risk factor associated with acute rejection, univariate logistic regression analysis were used to screen all potential risk factors, and multivariate logistic regression analysis were used to calculate odds ratios for the associations between acute rejection occurrence and ABOcompatible transplantation while adjusting for other risk factors of acute rejection. Variables in the final multivariate logistic regression model included ABO-compatible transplants (0 = identical, 1 = compatible), patient and donor race (0 = white, 1 = non-white), patient age, total ischemic time (hours), multiorgan transplantation (0 = intestine alone, 1 = multivisceral transplantation with liver, 2 = multivisceral transplantation without liver), induction immunosuppression (0 = No, 1 = Yes), and number of maintenance of immunosuppression. ABOcompatible transplantation had an odds ratio of 1.85 with a p-value of 0.001.
To establish multivariate Cox models, the registry data were first explored using univariate analyses to screen for potential predictors of graft loss. The log-rank test was used for categorical variables, whereas univariate Cox proportional hazard (Table 3 ). In the final multivariate Cox analyses, data were reported as a hazard ratio (relative risk of graft failure) with a 95% confidence interval. Two-sided p-value less than 0.05 were considered significant.
Results

ABO-compatible transplant recipients include blood group
A and B patients who received transplants from O donors and blood group AB patients who received transplants from A, B, or O donors. Figure 1A A significantly higher percentage of ABO-compatible intestinal transplant recipients experienced acute rejection than ABO-identical transplant recipients (Table 4 , 77% vs. 64%, p < 0.0001). This comparison is based on the data collected before discharge since the reporting rates of acute rejection at 6 months and 1-year post-transplant were low (47-63%). The association between occurrence of acute rejection and ABOcompatible transplantation was further verified in univariate and multivariate logistic regression analyses (see Materials and Methods for a detailed description). There is no difference between groups in the total number of rejection episodes each patient experienced (p = 0.7777). ABO-compatible transplant recipients had a significantly lower 10-year graft survival rate than ABO-identical transplant recipients (Figure 2A) . A more significant graft survival difference was observed in the intestine-alone transplantation which occurred within the 1st year post-transplant ( Figure  2B ). Transplantation of intestine with liver seemed to reduce the significance of the graft survival difference between ABOcompatible and identical transplants ( Figure 2C ). As described in the materials and methods section, after adjustment of all influencing variables, multivariate Cox analysis confirmed the association between ABO-compatible transplantation and graft failure, with a hazard ratio of 1.42 (p < 0.001).
A total of 1,150 ABO-identical and 129 ABO-compatible transplant recipients lost allografts post-transplant. Causes of graft failure were reported to the registry for 525 (45.65%) ABOidentical and 63 (48.84%) compatible transplant recipients. Figure  3 shows that immunological causes (acute and chronic rejection) accounted for 52.5% and 54.0% of graft loss in ABO-identical and compatible transplantation, respectively. Interestingly, acute rejection alone accounted for 41% of all graft loss in ABOcompatible transplant recipients, which was significantly higher than that in ABO-identical transplant patients (25%, p = 0.041).
Discussion
In this study, very surprisingly, we found ABO-compatible intestinal transplant recipients had a significantly higher chance of experiencing acute rejection than ABO-identical transplant recipients. More importantly, these patients also had a significantly lower rate of long-term graft survival. Analysis of the causes of graft failure indicates that acute rejection accounted for 41% of graft loss in ABO-compatible transplantation, which is significantly higher than that in ABO-identical transplantation (25%).
The major concern for ABO-compatible but non-identical transplantation is the potential risk of GVH antibodies against mismatched recipient ABO antigens. GVH antibodies might be obtained from plasma transfusions of donor type or from passive transfer of donor-derived antibodies [9] [10] [11] . It has also been proven that GVH antibodies can be produced by viable graftderived lymphocytes from lymphoid tissues of transplants [10] [11] [12] [13] . Bakr, et al. [14] reported that in ABO-compatible kidney transplantation, GVH antibodies causes hemolysis at the frequency of 60%. Possibly due to the fact that kidney transplant contains fewer GVH antibodies and GVH antibody-producing cells, GVH antibody-induced hemolytic anemia was mild and does not cause serious consequences in kidney transplantation. In liver transplantation, with presumably more GVH antibodies or GVH antibody-producing cells, Koukoutisis [6] and Bjoro [7] reported that ABO-compatible transplant recipients have significantly lower graft and patient survival compared to ABO-identical transplant patients. The intestine possesses the largest mass of lymphoid tissue of any solid organ in the human body [15] . Not surprisingly, therefore, intestinal transplantation is reported to have a higher rate of GVH disease (GVHD, 5.6%-9.1%) [16] [17] [18] than a transplant of any other organ type, including liver (1-2%) [19, 20] . Since GVHD in transplant recipients is associated with a very high mortality rate (up to 85%) [18] and intestinal transplant recipients have a high rate of GVHD, this may explain why ABO-compatible transplants have a lower graft survival than identical transplants.
Graft loss and patient death in intestinal transplant recipients with GVHD have been reported to be associated with the infection since GVH reactions may damage host lymphoid tissues and produce profound immunosuppression [18, 21] . However, in this study, the percentage of graft loss due to infection is only slightly higher incompatible transplants than identical transplants (14.3% vs. 10.7%), while graft loss resulting from acute rejection is much higher incompatible transplants than in identical transplants (41.3% vs. 25.3%). These data imply that there might be a potential association between GVH reactions and acute rejection. Peyer's patch is used as a representative intestinal lymphoid tissue. In ABO-compatible but unmatched transplantation, host RBC, platelet, and other cells with mismatched host's alloantigens (ABO, HLA etc.) on the surface may trigger GVH antibody responses in intestinal lymphoid tissues. B) GVH antibody-induced hemolysis and coagulation. GVH antibodies against host RBC surface antigens bind and lyse host RBC-hemolysis, which activate coagulation and blood clot formation via both intrinsic and extrinsic pathways. Blood clot formation results in allograft ischemia and consequent tissue injury and dysfunction. C) Enhanced clot formation by GVH antibodies. Primary endothelium injury of intestinal transplant might be induced by various risk factors which include patient's immune reaction against graft's antigens or by allograft ischemia and reperfusion. Endothelia injury activates coagulation and clot formation. GVH antibodies against both platelets and RBCs, the major components of a blood clot, further enhance the formation of the clot and deteriorate the ischemic injury of the allograft.
In the diagnosis of allograft rejection in intestinal transplants, lymphoid activation is commonly found in the Peyer's patch (a closely aggregated nodule of lymphoid tissue in the wall of the small intestine) of the allograft [22] . However, activated lymphocytes in the graft Peyer's patch may be of either recipient or donor origin. Activated lymphocytes of recipient origin demonstrate an active host versus graft immunity; while if activated lymphocytes are of donor origin, GVH immune responses are indicated. Interestingly, in a rat small bowel transplant rejection model, donor lymphocytes became more activated than recipient lymphocytes in the graft mesenteric lymph node and Peyer's patches. The presence of more activated GVH immune responses suggests that GVH immunity may contribute to graft damage [23] . Unfortunately, from this registry database analysis, we could not determine whether the allograft rejection and consequent graft loss in the ABOcompatible transplant group are associated with GVH disease since information on patients' GVH disease and biopsy reports of cases of rejection is not available in the registry data.
We propose that in ABO-compatible intestinal transplantation, GVH immune reactions against mismatched host blood type antigens may participate in the pathogenesis of transplant rejection through two potential mechanisms. Certainly, other mismatched host alloantigens, such as Human Leukocyte Antigens (HLA), may also trigger GVH immune responses.
The first potential mechanism of GVH immunity participating in allograft rejection involves intravascular hemolysis, which results from GVH immune responses against mismatched recipient blood type antigens. When an allograft from a blood type O donor is transplanted to a blood type A recipient (host), immune cells (e.g. GVH plasma cells) from the graft will mount immune responses (e.g. GVH antibodies) against surface antigens of host blood cells [ABO antigens on Red Blood Cells (RBCs) and platelets, and HLA antigens on platelets, etc.] ( Figure 4A ). These GVH antibodies produced by graft lymphoid tissues against host RBCs will cause intravascular hemolysis in ABO-compatible transplant recipients ( Figure 4B ). Coagulation activity of hemolysis has been discovered and confirmed for decades [24] [25] [26] [27] [28] . The clinical consequence of coagulation depends on the severity of intravascular hemolysis. It has been reported that acute massive intravascular hemolysis may sometimes cause Disseminated Intravascular Coagulation (DIC), the most severe form of coagulation [27, 28] . In ABO-compatible intestinal transplantation, the amount of anti-host RBC antibodies produced from GVH reactions might not be high enough to rapidly cause systemic symptoms like DIC as reported in transfusion reactions [29] and in a large dose IVIG treatment [28] . However, the effects of these GVH antibodies on induction of immune hemolysis, activation of platelet aggregation/coagulation, and formation of blood clots will certainly be harmful to the function of the allograft. The clinical manifestations of this GVH antibodyinduced hemolysis and consequent coagulation/clot formation may perfectly mimic allograft rejection caused by the host versus graft immunological reactions. However, it is still possible to distinguish the tissue injuries resulting from these two different causes since GVH antibody-induced hemolysis and consequent clot formation will affect not only the allograft itself, but also the patient's native tissues, while inflammatory changes of allograft rejection are only seen within the intestinal graft itself.
The second potential mechanism of GVH immunity participating in allograft rejection involves the enhanced platelet aggregation, coagulation, and clot formation in the vasculature of the intestinal allograft ( Figure 4C ). Primary endothelial injury of intestinal transplant may be initiated by a patient's immune reaction against the graft antigens or by allograft ischemia and reperfusion. Endothelial injury activates the coagulation cascade in which the recipient's platelet is the major player in forming a blood clot. The consequences of blood clot formation in the vasculature include ischemia and even infarction of graft tissues supplied by clotted vessels. The secondary tissue damage following primary endothelial injury will further deteriorate the allograft function, which finally results in graft failure [30] . In ABO-compatible intestinal transplantation (e.g. O donor to A recipient) with a large quantity of lymphoid tissue, the transplant may contain enough of the recipient's antigen-specific immune cells that will mount GVH immune responses against mismatched recipient's antigens. These antigens include not only ABO blood type antigens, but also HLA antigens, which are all expressed on the surface of platelets [18] [19] [20] [21] . Either GVH HLA-or ABO-specific antibodies will bind to platelets or other blood cells of recipient origin at the site of activation of coagulation, which further enhances the formation of blood clots and results in graft failure.
Since this is a database analysis, findings and conclusions drawn from this study might be limited by the availability and integrity of variables of the database. Major limitations of this study include: 1) a high rate of missing observations for some variables; and 2) hypothesized mechanisms to be proven. Some variables show potential association with graft failure in univariate Cox analysis, such as donor Epstein-Barr virus sera status, patient hepatitis C virus sera status, patient hepatitis B virus surface antigens, patient cytomegalovirus immunoglobulin antibodies, patient liver dysfunction at transplantation, etc. However, there are 27-62% of patients with no information about these potential failure predictors. Therefore, they have to be excluded from multivariate Cox analysis to avoid selection bias. Exclusion of key variables from the analysis may affect the accuracy of the analysis. Even though we proposed potential mechanisms regarding how GVH reactions are involved in allograft injuries, there was no direct evidence from registry data to support these hypotheses. Further investigations are required to prove these hypotheses.
In conclusion, ABO-compatible intestinal transplants were associated with a higher rate of acute rejection and a lower rate of long-term graft survival as compared to ABO-identical transplants. We need to seriously reconsider the strategies to deal with ABO-compatible transplants. First, it is reasonable to avoid ABO-compatible transplantation when an identical donor is available. Certainly, this must be balanced against the potential risk of waiting for an ABO-identical donor in the face of imminent death from liver failure. In addition, the patient's sensitization to HLA antigens needs to be considered, especially when donor specific antibodies are preexisting. Second, when ABOcompatible transplant is the only choice, the recipient deserves a more intense induction or maintenance immunosuppression to minimize the potential risk of GVH immune reactions. Third, monitoring patients for GVH immune reactions (GVH ABO or HLA antibodies, effector T-cells, et al), especially within the 1 st year post-transplant, may help to identify patients under risk of acute rejection and graft failure who need to be treated accordingly. Last, when RBC transfusion is needed for an ABO-compatible transplant recipient with detectable GVH antibodies, donor-type packed RBCs are recommended and should be washed to remove anti-recipient antibodies. In contrast, plasma should be of recipient's ABO type. Since a recipient type RBC transfusion will increase the target cells of GVH antibodies and a donor type plasma transfusion will increase the effectors-GVH antibodies, both will further intensify the GVH reaction-induced graft injury.
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